Mesenchymal stem cell-based product for
acute graft-versus-host disease

TEMCELL® HS Inj. is the world’s first therapeutic product using mesenchymal stem cells for the treatment of acute graft-versus-host disease (acute GVHD), a severe complication arising from hematopoietic stem cell transplant. The product was approved in September 2015 as Japan’s first allogeneic regenerative medical product and launched in February 2016.

TEMCELL® HS a innovative product of isolated and expanded mesenchymal stem cells (MSCs) derived from bone marrow aspirate of a healthy adult donor. Being an off-the-shelf product, it is widely available for patients in need, and we expect TEMCELL® HS Inj. to be a new treatment option for patients with Acute GVHD. Ultra-low temperature must be kept during transportation of TEMCELL® HS Inj. in order to maintain its quality. We operate an ultra-low cold chain system jointly developed with MEDIPAL HOLDINGS CORPORATION to ensure timely delivery of high-quality products to clinical sites across Japan.
・Acute graft-versus-host disease following hematopoietic stem cell transplant